Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity

By afschroeder • October 13, 2025

Li YR, Shen X, Zhu Y, Li Z, Hon R, Tian Y, Huang J, Zhao AS, Ma NY, Zhang C, Lin D, Sargsyan K, Yuan Y, Yang L. Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity. J Hematol Oncol. 2025 Oct 13;18(1):86. doi: 10.1186/s13045-025-01736-9. PMID: 41077583.

Tags: allogeneic CAR-NKT cells, Allogeneic cell therapy, allorejection, Cedars Sinai DoM, CRISPR-Cas9 gene editing, Hematology/Oncology, HLA ablation, Mesothelin-targeting CAR (MCAR), Metastatic model, Multiple tumor targeting mechanism, Off-the-shelf, Orthotopic model, Potent antitumor activity, Publications, Triple-negative breast cancer (TNBC), tumor microenvironment (TME), Tumor-associated macrophage (TAM)

Related Posts

A CD57+ CD8 T cell subset links cytotoxic T cell cytotoxicity to fibrotic lung disease in systemic sclerosis

Sasaki T, Cao Y, Sowerby JM, Higashioka K, Marks KE, Elahee M, Kamiya M, Dellaripa PF, Ainsworth RI, Taylor KE, Bottini N, Wolters P, Kim[...]

Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and Design

Plutzky J, Taub PR, Bhatt DL, Al Dhaybi O, Aroda VR, Basile JN, Bloch MJ, Budoff M, Busch RS, Buse JB, Cheung D, Christofides EA,[...]

Corrigendum to “Deep learning in fetal, infant, and toddler neuroimaging research”[Dev. Cognit. Neurosci. (2026), 101680]

Chin JH, Wyburd MK, Ayzenberg V, Bayet L, Bilgic B, Chen EM, Chen Y, Dineen Á, Fujita S, Liu J, Jun Y, Camacho MC, Zöllei[...]